Index

Access to medical procedures 48–52
cause against patent protection 50
control, question of 50–52
demand and supply, dynamics of 51–52
increased costs of health care 52–53
meanings 49
methods of medical treatment 48–50

Actavis v Merck 361–372
Court of Appeal 362–364
‘different medical condition’ 368
distinct and different medical condition 366
first instance 361–362
novel technical features 363
obviousness 364–365
precedent 371
which novelty? 370–371

Animals 101–112
agricultural methods 102
application by TBAs 103–104
EBA 111–112
ectoparasitic infestations of pigs 103–104
immunostimulation 107–108
incidental objectives 106–111
increased meat production 108–109
industrial application 101–106
legislative history 104–105
method of treatment by therapy 109–110
reformulation of exclusion 106
surgical methods 111–112
therapy, meaning 110

Arguments against patent protection 41–70, 443–444
access to medical procedures 48–52
case against patent protection 50
control, question of 50–52
demand and supply, dynamics of 51–52
increased costs of health care 52–53
meanings 49
methods of medical treatment 48–50
breach of patient’s privacy 68–69
disclosure 69
right to privacy 68–69
code of ethics 61–62
compulsory licences 53–58
Act of 1977 54–55
case for 56
costs, and 57
intellectual property rights 53
limitations 57–58
meaning 53
public health, and 55–56
emotive arguments 41–42
Hippocratic Oath 61–62
methods of medical treatment 63–65
specific to medical profession 63–64
incitement structures 66–68
alternative 67
methods 43–45
pharmaceutical products 43–45
physician liberty and autonomy 58–60
factors affecting judgment 59
physician/patient relationship 60–61
products 43–45
public health implications 45–58
rationale for exclusion 42
right to health 46–48
Medical patent law – the challenges of medical treatment

- sharing norm 62–63
- erosion of 65
- methods of medical treatment 63–65
- nature of 64–65
- TRIPs Agreement 47
- Arguments for and against patent protection 443–447
- Arguments for patent protection 9–40, 444–445
- balancing exercise 443
- direct control over supply of invention 444
- economic purpose 10
- economic rationale 444
- ethical justifications 443–444
- incentive to disclose 11–13
- Chamberlain family 12
- methods of medical treatment 11–13
- research, and 13
- incentive to invent/innovate 14–23
- breadth of medical science 22
- cost-benefit analysis, and 22
- cost of research, and 17
- Gocyk-Farber on 21–22
- high development cost inventions 20–23
- methods of medical treatment 15–18
- promotion of R&D 16
- reward theory 14–15
- SET Patent 18–20
- utilitarian principles 14
- liberty/autonomy 34–39
- collaborative research efforts 38
- Hegel on 36
- Locke’s theory of property 35–36
- methods of medical treatment 38–39
- property rights, justification for 36–37
- Radin on 37
- rights of creator of invention 39
- prospect theory 23–26
- Kitch on 23–24
- limitation 24
- methods of medical treatment 25–26
- simple methods of treatment 26
- treatment regimes 25–26
- rationales 9–10
- rent dissipation theory 27–31
- Grady and Alexander on 27–30
- methods of medical treatment 28–31
- reward/desert 31–34
- endocrine therapy 33
- identity of creator 34
- methods of medical treatment 33–34
- philosophical difficulties 32
- value of product to society 33–34
- Australia
- judicial determination of exclusion 434
- public interest 446
- Commonwealth
- manner of new manufacture see Manner of new manufacture
- Contraceptive methods 97–100
- feminine hygiene device 99–100
- LHRH composition 97
- manner of new manufacture see also Manner of new manufacture
- arrangement of pills on card 317–319
- hormonal drugs 316
- method of medical treatment, whether 316
- pack claims 316, 317–320
- process claims 316
- royal prerogative 317
- setting limits 320–321
- method of treatment by therapy, whether 97–98
- personal use 98–100
- susceptible to industrial application, whether 98–100
- Cosmetic methods 89–96
- acceptable form of claim 95–96
- anti-snoring means 94
- appetite suppressant 91
- cleaning plaque 93–94
- industrial application 94–95
- meaning 90
### Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>not patentable</td>
<td>93–94</td>
</tr>
<tr>
<td>patentable</td>
<td>90–92</td>
</tr>
<tr>
<td>Patents Act 1977 see Patents Act 1977</td>
<td>90–92</td>
</tr>
<tr>
<td>thanoyl peroxide</td>
<td>90</td>
</tr>
<tr>
<td>therapeutic use, and</td>
<td>91–92</td>
</tr>
<tr>
<td>Diagnostic methods</td>
<td>184–228</td>
</tr>
<tr>
<td>application of principles</td>
<td>208–218</td>
</tr>
<tr>
<td>consistency of approach</td>
<td>218</td>
</tr>
<tr>
<td>defining diagnostic methods</td>
<td>208–212</td>
</tr>
<tr>
<td>interaction with human or animal body</td>
<td>213</td>
</tr>
<tr>
<td>intermediate steps</td>
<td>216–218</td>
</tr>
<tr>
<td>methodological issues: early view</td>
<td>213</td>
</tr>
<tr>
<td>methodological issues: more recent view</td>
<td>214–216</td>
</tr>
<tr>
<td>no diagnosis</td>
<td>209</td>
</tr>
<tr>
<td>no diagnosis and not practised on body</td>
<td>210</td>
</tr>
<tr>
<td>only examination and data gathering phase</td>
<td>210–212</td>
</tr>
<tr>
<td>present</td>
<td>210–212</td>
</tr>
<tr>
<td>practised on human or animal body</td>
<td>213</td>
</tr>
<tr>
<td>‘applied to the human or animal body’</td>
<td>188–189</td>
</tr>
<tr>
<td>blood extraction method</td>
<td>193–194</td>
</tr>
<tr>
<td>broad approach</td>
<td>196–201</td>
</tr>
<tr>
<td>application of general principles</td>
<td>200–201</td>
</tr>
<tr>
<td>blood extraction method</td>
<td>199</td>
</tr>
<tr>
<td>defining diagnostic methods</td>
<td>196–197</td>
</tr>
<tr>
<td>medical practitioners, involvement of</td>
<td>197–198</td>
</tr>
<tr>
<td>mental acts</td>
<td>196–197</td>
</tr>
<tr>
<td>practised on human or animal body</td>
<td>198–199</td>
</tr>
<tr>
<td>ultimate responsibility of physician</td>
<td>198</td>
</tr>
<tr>
<td>defining</td>
<td>189–192</td>
</tr>
<tr>
<td>EPO jurisprudence</td>
<td>439–440</td>
</tr>
<tr>
<td>examination phase</td>
<td>193</td>
</tr>
<tr>
<td>four-pronged test</td>
<td>190–191</td>
</tr>
<tr>
<td>legislative history</td>
<td>187–189</td>
</tr>
<tr>
<td>medical practitioners, involvement of</td>
<td>192–194</td>
</tr>
<tr>
<td>narrow approach</td>
<td>189–196</td>
</tr>
<tr>
<td>new medical technology</td>
<td>218–228</td>
</tr>
<tr>
<td>EU Biotech Directive see EU Biotech Directive</td>
<td></td>
</tr>
<tr>
<td>genetic diagnostic testing</td>
<td>219–221, 223–227</td>
</tr>
<tr>
<td>methods of medical treatment</td>
<td>219–221</td>
</tr>
<tr>
<td>morality, and</td>
<td>222–223</td>
</tr>
<tr>
<td>ordre public</td>
<td>222–223</td>
</tr>
<tr>
<td>patent law, and</td>
<td>218–219</td>
</tr>
<tr>
<td>non-invasive measurement</td>
<td>191–192</td>
</tr>
<tr>
<td>Patents Act 1977 see Patents Act 1977</td>
<td>90–92</td>
</tr>
<tr>
<td>practised on human or animal body</td>
<td>194–196</td>
</tr>
<tr>
<td>reconciling two approaches</td>
<td>201–208</td>
</tr>
<tr>
<td>delineating scope of</td>
<td>204–205</td>
</tr>
<tr>
<td>diagnosing diagnostic methods</td>
<td>201–206</td>
</tr>
<tr>
<td>essential features of claims</td>
<td>205–206</td>
</tr>
<tr>
<td>first principles</td>
<td>202</td>
</tr>
<tr>
<td>intellectual exercise</td>
<td>203–204</td>
</tr>
<tr>
<td>medical practitioners, involvement of</td>
<td>206–207</td>
</tr>
<tr>
<td>multi-step approach</td>
<td>202–203</td>
</tr>
<tr>
<td>practised on human or animal body</td>
<td>207–208</td>
</tr>
<tr>
<td>rationale for exclusion</td>
<td>201–202</td>
</tr>
<tr>
<td>scope of exclusion</td>
<td>184–185</td>
</tr>
<tr>
<td>Disclaimers</td>
<td>168–182</td>
</tr>
<tr>
<td>cosmetic method with therapeutic effect</td>
<td>170–171</td>
</tr>
<tr>
<td>EBA, and</td>
<td>180–181</td>
</tr>
<tr>
<td>excluded method of medical treatment</td>
<td>174–175</td>
</tr>
<tr>
<td>flow measurement</td>
<td>171–172</td>
</tr>
<tr>
<td>form of admissible claim</td>
<td>175–178</td>
</tr>
<tr>
<td>higher level of abstraction</td>
<td>177–178</td>
</tr>
<tr>
<td>implications of using</td>
<td>178–180</td>
</tr>
<tr>
<td>importance of</td>
<td>169–170</td>
</tr>
<tr>
<td>issue</td>
<td>169–170</td>
</tr>
<tr>
<td>legal analysis</td>
<td>182</td>
</tr>
<tr>
<td>limiting scope of claims, and</td>
<td>172</td>
</tr>
</tbody>
</table>
methods of medical treatment, and 170–175
‘non therapeutic’, meaning 173–174
omission of step 181–182
surgical methods, and 168–182
use of 175–176
when allowed 175–176
wording of claims, and 171
Dosage regimes
Patents Act 1977 see Patents Act 1977
Enlarged Board of Appeal (EBA) animals, and 111–112
disclaimers, and 180–181
MEDI-PHYSICS/Treatment by surgery, and 140–148
surgical methods, and 123–124, 136–138, 153
therapeutic methods, and 85–87
EU Biotech Directive 221–223
aim of 221
methods of medical treatments 221–222
morality, and 222–223
ordre public 222–223
European Patent Office (EPO) jurisprudence 436–442
diagnostic methods 439–440
 genetic diagnostic testing 224–227
legislative history 436
medical treatment 5–6
second and further medical uses 440–442
surgical methods 438–439
therapeutic methods 436–438
United Kingdom courts, and 442
Excluded surgical step 158–168
applicable national laws 161–162
diagnostic methods 160–161
existence of surgical steps in claim 159–161
insertion of device into human body 162–163
interaction with body 158
MEDI-PHYSICS/Treatment by surgery 165–168
method for conditioning gas 163
non-surgical steps, and 159–160
ratio legis 161–162
surgical steps defined as excluded surgical treatments 162–164
surgical steps not defined as excluded surgical treatments 164–165
Genetic diagnostic testing 223–227
challenges 228
EPO jurisprudence 224–227
morality, and 223–227
nucleic acid 224–226
ordre public, and 223–227
socio-economic consequences of patenting 226–227
Hippocratic Oath 61–62
methods of medical treatment 63–65
specific to medical profession 63–64
Judicial determination of exclusion 433–436
Australia 434
New Zealand 434
United Kingdom 433–434
PAT 434
United States of America 435–436
Manner of new manufacture 287–331
Australia 321–330
ethical considerations 324
law 299
public policy 323
vendible test 322–323
biological subject matter 301–304
biotechnological subject matter 301–304
commercial object requirement 297–298
Commonwealth 321–330
contraceptive methods 315–321
arrangement of pills on card 317–319
hormonal drugs 316
method of medical treatment, whether 316
pack claims 316, 317–320
### Index

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Process claims</td>
<td>316</td>
</tr>
<tr>
<td>Royal prerogative</td>
<td>317</td>
</tr>
<tr>
<td>Setting limits</td>
<td>320–321</td>
</tr>
<tr>
<td>Diagnostic methods, and</td>
<td>291–292</td>
</tr>
<tr>
<td>Deafness, and</td>
<td>290–291</td>
</tr>
<tr>
<td>Demise of commercial object requirement</td>
<td>299–301</td>
</tr>
<tr>
<td>Economic rationale of patent system</td>
<td>300–301</td>
</tr>
<tr>
<td>Ethical grounds</td>
<td>308–315</td>
</tr>
<tr>
<td>Extraction of lead</td>
<td>297</td>
</tr>
<tr>
<td>Medicine, meaning</td>
<td>288</td>
</tr>
<tr>
<td>Micro-organisms</td>
<td>302–303</td>
</tr>
<tr>
<td>Morality: emerging concept</td>
<td>309–311</td>
</tr>
<tr>
<td>Morality: legal justification</td>
<td>311–314</td>
</tr>
<tr>
<td>Morality: necessary or hindrance, whether</td>
<td>314–315</td>
</tr>
<tr>
<td>Morality, relevance</td>
<td>308</td>
</tr>
<tr>
<td>Nature of exclusion</td>
<td>288–295</td>
</tr>
<tr>
<td>New Zealand</td>
<td>321–330</td>
</tr>
<tr>
<td>EISAI</td>
<td>327–329</td>
</tr>
<tr>
<td>New use claim</td>
<td>325–326</td>
</tr>
<tr>
<td>Novelty</td>
<td>326</td>
</tr>
<tr>
<td>Public policy</td>
<td>324–325</td>
</tr>
<tr>
<td>Second medical indication</td>
<td>327–329</td>
</tr>
<tr>
<td>Second medical use patents</td>
<td>325–329</td>
</tr>
<tr>
<td>Swiss-type claims</td>
<td>327, 329</td>
</tr>
<tr>
<td>Patent Office Practice</td>
<td>287, 304–307</td>
</tr>
<tr>
<td>Act of 1977</td>
<td>307</td>
</tr>
<tr>
<td>Contraception</td>
<td>305</td>
</tr>
<tr>
<td>Examiners, role of</td>
<td>307</td>
</tr>
<tr>
<td>Improved wool yield</td>
<td>304–305</td>
</tr>
<tr>
<td>PAT, role of</td>
<td>307</td>
</tr>
<tr>
<td>Procedure</td>
<td>306–307</td>
</tr>
<tr>
<td>Reduction of gastric secretion</td>
<td>306</td>
</tr>
<tr>
<td>Public policy grounds</td>
<td>308–315</td>
</tr>
<tr>
<td>Rationale for exclusion</td>
<td>295–315</td>
</tr>
<tr>
<td>Sound treatment</td>
<td>302–303</td>
</tr>
<tr>
<td>Statute of Monopolies</td>
<td>296</td>
</tr>
<tr>
<td>Statutory interpretation</td>
<td>296–304</td>
</tr>
<tr>
<td>Statutory regime</td>
<td>296</td>
</tr>
<tr>
<td>Test for general patentability</td>
<td>300</td>
</tr>
<tr>
<td>Treatment in animals</td>
<td>293–295</td>
</tr>
<tr>
<td>Treatment in humans</td>
<td>289–292</td>
</tr>
<tr>
<td>Vendible product</td>
<td>298</td>
</tr>
<tr>
<td>Widening conception of manufacture</td>
<td>298</td>
</tr>
<tr>
<td>Medical treatment</td>
<td>5–6</td>
</tr>
<tr>
<td>EPO jurisprudence</td>
<td>5–6</td>
</tr>
<tr>
<td>Future of medical patents</td>
<td>7–8</td>
</tr>
<tr>
<td>Patent protection</td>
<td>1–2</td>
</tr>
<tr>
<td>Arguments</td>
<td>2–5</td>
</tr>
<tr>
<td>Direct control</td>
<td>5</td>
</tr>
<tr>
<td>Public health, and</td>
<td>3–4</td>
</tr>
<tr>
<td>Patentability</td>
<td>6–7</td>
</tr>
<tr>
<td>Medicine meaning</td>
<td>288</td>
</tr>
<tr>
<td>New medical technology</td>
<td>112–116</td>
</tr>
<tr>
<td>DNA technology</td>
<td>113–114</td>
</tr>
<tr>
<td>Gene therapy</td>
<td>113–115</td>
</tr>
<tr>
<td>Germline gene therapy</td>
<td>114–115</td>
</tr>
<tr>
<td>Somatic gene therapy</td>
<td>114–115</td>
</tr>
<tr>
<td>Stem cell therapy</td>
<td>115</td>
</tr>
<tr>
<td>Therapeutic cloning</td>
<td>113–115</td>
</tr>
<tr>
<td>New Zealand economic rationale</td>
<td>446</td>
</tr>
<tr>
<td>Judicial determination of exclusion</td>
<td>434</td>
</tr>
<tr>
<td>Manner of new manufacture</td>
<td>see Manner of new manufacture</td>
</tr>
<tr>
<td>Patent Appeal Tribunal judicial determination of exclusion</td>
<td>434</td>
</tr>
<tr>
<td>Patent Office Practice, and</td>
<td>307</td>
</tr>
<tr>
<td>Patents Act 2004</td>
<td>332–373</td>
</tr>
<tr>
<td>Basis of origin of exclusion, and</td>
<td>333–334</td>
</tr>
<tr>
<td>Comparison with pre-1977 law</td>
<td>333–338</td>
</tr>
<tr>
<td>Interpretation</td>
<td>332–333</td>
</tr>
<tr>
<td>Revision of EPC, and</td>
<td>332</td>
</tr>
<tr>
<td>Patents Act 1977</td>
<td>334–338</td>
</tr>
<tr>
<td>Actavis v Merck</td>
<td>see Actavis v Merck</td>
</tr>
<tr>
<td>Animals, treatment of</td>
<td>see also Animals</td>
</tr>
<tr>
<td>Application of exclusion</td>
<td>338–344</td>
</tr>
<tr>
<td>Defining therapy</td>
<td>339–340</td>
</tr>
<tr>
<td>Ex post facto rationalisation</td>
<td>338–339</td>
</tr>
<tr>
<td>Inherent contradictions</td>
<td>339</td>
</tr>
</tbody>
</table>
method of treatment by therapy 339–342
pharmaceutical inventions 338
taxol 340–342
Bristol-Myers Squibb, and 361–370
cosmetic methods 337–338
diagnostic methods 336–337, 343–344
dosage regimes 356–372
Actavis v Merck 361–372
issues for courts 357
second medical treatment 357–360
further reformation of exclusion 335–336
humans, treatment of 336
industrial application 335
invention 334–335
methods of treatment by surgery 342–343
new law of patents 334
reformulation of exclusion 335
second and further medical uses 345–356
applying requirements of Swiss-type claim 353–355
codification of EISAI/Second medical indication 355–356
current UK approach 348–353
desire to achieve conformity 347–348
doctrinal issues 346–356
dosage regime 352–353
EISAI 345–346
manufacture of medicament 353–354
new therapeutic application 354–355
novelty in end result 350–351
only first medical use protected 346
pharmaceutical inventions 347
principle, matter of 347
reaffirmation by Court of Appeal 349–353
reluctant application by Jacob J 348–349
second medical indication 345–346
Swiss-type claim 351–352
taxol 349–353
Public health considerations 433
Royal prerogative contraceptive methods and 317
Second and further uses see also Second and further medical uses claims allowable, whether 252–253 ‘compounds’ 232
devices 246–254
dosage regimes 255–285
controversy over 255–256
decisions of TBAs 279–280
defining 280–281
differences between EPC 1973 and EPC 2000 281–282
end of Swiss type claims 282–283
EPC 1973 261–269
EPC 2000 259–261, 269
first medical uses 273–274
new technical effect 281
relationship with medical treatment exclusion 271–273
second and further medical uses 256–259
specific uses under EPC 2000 274–277
Swiss-type claims 277–279
EISAI 235–237
EPO jurisprudence, and 440–442
extending reach of EISAI principle 244–246
administration of vaccine to sero-postive pigs 244–245
initial exclusion 234–235
instruments 246–254
claims allowable, whether 252–253
recent changes 253
legislative history 230–234
new medical technology 285–286
not applicable to products which are not medicaments 251
not falling within ratio legis of
ESAI/second medical
indication 249–251
origin 234–237
Second and further medical uses see
also Second and further uses
Patents Act 1977 see Patents
Act 1977
reform of EPC 254–255
‘substance’ 232–233
Swiss-type claims see Swiss-type
claims
treatment regimes 255–285
corresponding over 255–256
decisions of TBAs 279–280
differences between EPC 1973
and EPC 2000 281–282
end of Swiss-type claims 282–283
EPC 2000 259–261
first medical uses 273–274
new technical effect 281
relationship with medical
treatment exclusion
271–273
second and further medical
uses 256–259
specific uses under EPC
2000 274–277
Swiss-type claims 277–279
SET patent 18–20
funding 19
Surgical methods 117–183
animals 121–122
biotechnology, and 122
broadening of definition 183
cosmetic methods 148–153
beautifying human body
150–151
EBA in MEDI-PHYSICS/
Treatment by surgery 153
purpose test 149–151
removal of excess hair 150
technical features of
claims 151–153
tightening skin surface
151–152
defining 124–138
dental treatment 155–156
diagnostic method 154
disclaimers see also
Disclaimers 168–182
EBA in CYGNUS/Diagnostic
method 136–138
EBA, referral to 123–124
EPO jurisprudence 438–439
exception 131–132
excluded surgical step 158–168
applicable national laws
161–162
diagnostic methods 160–161
existence of surgical steps in
claim 159–161
insertion of device into human
body 162–163
interaction with body 158
MEDI-PHYSICS/Treatment by
surgery 165–168
method for conditioning gas 163
non-surgical steps, and 159–160
ratio legis 161–162
surgical steps defined as excluded
surgical treatments 162–164
surgical steps not defined as
excluded surgical
treatments 164–165
expansive definition 125
hair removal method 121
interpretive criteria 155–157
intervention on structure of
organism 156–157
issues relating to 118
legislative history 119–123
MEDI-PHYSICS/Treatment by
surgery 138–148
apparatus for skin
resurfacing 142
broad or narrow construction of
exclusion 143–144
decision of EBA 140–148
decision of TBA 138–140
hair removal method 142
legal analysis 146–148
literal interpretation 140–141
ratio legis of exclusion 141–143
redefining methods of treatment
by surgery 144–146
treatment by therapy 141
medical practitioners, involvement
of 153–155
narrow interpretation 126–127
non-insignificant 129–130
pericardial access 124
physician, role of 153–155
polarized 129Xe 123–124
purpose of intervention 132–136
ratio legis 132–134
relevance 134–136
reason for exclusion 117
significance 157
surgery, meaning 128–129
therapeutic treatment, and
130–131
 travaux préparatoires 120
Swiss-type claims 237–244
acceptable form 242–244
adsorbent, use of 238–239
anti-tumoural agent 242–243
L (-) carnitine 241
manufacture of medicament 238–239
new therapeutic application 239–242
requirements 237–244
sea lice infestation 242
serotonin receptor 240–241
Therapeutic methods 71–116
animals see Animals
contraceptive methods see
Contraceptive methods
Cosmetic methods see also Cosmetic
methods
defining 75–78
EPO jurisprudence 436–438
implantable devices 78–88
application 86
blood assistance method 84–85
EBA 85–87
need for functional link or
nexus 79–80
not patentable 80–81
pacemaker 81–84
patentable 81–85
rapid acquisition resonance
imaging 87
therapeutic effect 88
involvement of medical
practitioners 88–89
legislative history 73–75
maintenance of health 77–78
medical treatments 73
methods of therapy 73–74
new medical technology see New
medical technology
‘physical methods’ 74
restoration of health 77–78
scope of exclusion 75–77
therapy, meaning 74–75
treatment by therapy,
meaning 72–73
Therapy
meaning 74–75, 75–76
Treatment by therapy
meaning 72–73
TRIPs Agreement 47, 54

United Kingdom courts
EPO jurisprudence, and 442
United Kingdom Patents Act 2004 see
Patents Act 2004
United States of America 374–432
applying Bilski v Kappos 422–430
applying machine-or-
transformation test 425–428
diagnosis for curative
purposes 420
interpreting claims 423–424
mental step 429–430
natural phenomena 428–429
relevance of machine-or-
transformation test 422–433
balancing of competing values and
interests 445
constitutional guarantee 392–393
constitutional power 392–431
creation of fever in human
body 379
diagnostic methods after Bilski v
Kappos 412–430
analysis of gene sequences
421–422
defining diagnostic
methods 413–415
mathematical formula 417–418,
419
laws of nature 416–417
Index

machine-or-transformation test 415–416
natural phenomena 416–422
process for curing synthetic rubber 418–420
diagnostic methods in Federal Circuit after Laboratory Corporation v Metabolite Labs 400–409
diagnostic methods in Federal Circuit before Laboratory Corporation v Metabolite Labs 394–395
diagnostic methods in Supreme Court 396–400
‘application of a law of nature’ 399
‘correlate’, meaning 396–399
‘natural phenomenon’ 399–400
‘process’ 399
public interest considerations 400
658 patent 396
Dick 378
ex parte Brinkerhoff 378–380
ex parte Scherer 374, 375
Federal Circuit 394–395
algorithm 394, 408
diagnostic claims 394–395
diagnostic methods after Laboratory Corporation v Metabolite Labs 400–409
fundamental principle 407
machine-or-transformation test 404
mental process 403–404
phenomena of nature 401–403, 406
transformation 407–408
‘warning’ steps 408–409
Genomic Research and Diagnostic Accessibility Act 390–392
contrary to spirit of MPAA 392
immunity from infringement 391
reason for 390
research on genetic sequences 391
retrospective application 391–392
infringement 390
inhaled ethers 375–376
initial exclusion 375–378
initial judicial determination 375–382
involvement of human body 380–381
judicial determination of exclusion 434
legal requirements of patentability 431
legislative history 383–384
legislative intervention 382–392
MPAA 382
MPAA 432
medical or surgical method 380
nature of exclusion in section 387(c) 384–390
cadavers 387
defendant 386
hybrid claims 389–390
legislative intention 385–390
medical activity 384–385, 386–387
patented use of composition of matter 387–389
three-pronged approach 385
patent protection reasserted 380–382
POBA 374
professional ethics 431
public policy 431
section 1, Patent Act 392–393
Senate Bill 1334 383
Supreme Court categories of inventions eligible for protection 410
diagnostic methods after Bilski v Kappos 412–430
machine-or-transformation test 410–411
process, test for 411
standard for patentability in Bilski v Kappos 409–412
surgical instruments 377
USPTO 374